| INTRODUCTION
Intrahepatic cholangiocarcinoma (iCCA) is the second most common liver malignancy and usually refractory to standard treatment, resulting in a high frequency of recurrence and mortality. 1 Among all the etiological factors of iCCA, hepatitis B virus (HBV) infection is attracting more attention 2,3 as HBV-related iCCA has been proved possessing distinct demographic and clinicopathologic features. Patients are more likely to be male and younger, have less lymphatic metastasis, higher serum levels of alpha-fetoprotein (AFP), and better outcomes. 4, 5 Moreover, compared with non-HBV-related iCCA, HBV-related iCCA is more likely to have cholangiolar differentiation, present with a mass-forming subtype, and express low N-cadherin. 6, 7 There is a concern that HBV-related iCCA might be recognized as a unique subtype of iCCA, and requires a more specific treatment.
A recent study found that liver cirrhosis and multiple tumors were independent of prognostic factors for the overall survival (OS) in HBV-related iCCA patients, and did not recommend routine lymph node dissection as lymphadenectomy did not significantly improve the survival rate, especially in patients with negative lymph node status. 8 There is no study comparing the prognostic factors between HBV-and non-HBV-related iCCA.
We truly believe determining more specific prognostic factors in these two subtypes of iCCA, which could help us better understand and treat them more precisely.
With the advancement in next-generation sequencing, it has become known that genetic aberrations, such as TP53, RAS, and RAF mutations could influence the outcome of iCCA patients. 9 Therefore, we investigated the prognostic value of demographic, clinicopathologic, and genetic factors in HBV-and non-HBV-related iCCA, respectively. To our knowledge, this study is also the first study that determines the prognosis prediction of TP53 and RAS/RAF mutations in HBV-and non-HBV-related iCCA. 
| MATERIALS AND METHODS

| Patients
| DNA extraction and sequencing
Genomic DNA of 166 snap-frozen iCCA samples from our institute was extracted using the QIAamp DNA Mini Kit (Qiagen, Valencia, CA) according to the manufacturer's instructions.
Sanger sequencing on exons 4 to 10 of TP53, exons 2 to 3 of KRAS and NRAS, and exon 15 of BRAF was carried out as previously described. 11 The primers used were listed in Supporting Information Table 1 . With respect to the 103 patients from Cohort B, the authors first applied the whole-exome sequencing to detect genetic alterations and then validated it through Sanger sequencing. The significantly mutated genes were identified by Genome-MuSiC at the end, which further corrected the results, including the false-positive deletions. 10 
| Follow-up
The clinical data of all patients from our institute was collected. The follow-up consisted of routine blood tests, physical examination, and abdominal ultrasonography, which was performed every 3 months for the first 2 years and twice a year, thereafter. The OS was set as the primary endpoint in this study and defined as the interval between the date of surgery and death. The follow-up data of the rest 103 patients was available online. The patients who were lost to follow-up or survived less than 30 days after surgery were excluded. respectively. The baseline characteristics of patients between cohorts A and B are described and compared in Table 1 . Serum levels of CA19-9, tumor number, tumor differentiation, and frequency of TP53 mutation were different.
| Statistical analysis
| The characteristics in HBV-and non-HBV-related iCCA
The demographic, clinicopathologic, and genetic features were compared between HBV-and non-HBV-related iCCA. As shown in Table 2 , when compared with non-HBV-related iCCA, patients of HBV-related iCCA were more likely to be younger males, who had liver cirrhosis, multiple lesions, higher frequency of TP53 mutation and serum levels of AFP, presented with less lymphatic metastasis, lower frequency of RAS/RAF mutation, and lower serum levels of CA19-9.
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| Prognostic markers in HBV-related and non-HBV-related iCCA
The prognostic value of clinicopathological and genetical aberrations was evaluated in HBV-and non-HBV-related iCCA, respectively. As shown in Table 3 , the factors predicting patients' OS were not exactly the same between HBV-and non-HBV-related iCCA, except in serum levels of CA19-9 and tumor differentiation.
In HBV-related iCCA, lower serum levels of AFP or CA19-9, Note. Bold value means difference was significant.
and worse outcomes. 6, 16 Moreover, HBV-and non-HBV-related iCCA have also shown distinctive genetic characteristics from each other. 10 In this study, we confirmed TP53 mutation more likely occurred in HBV-related iCCA and RAS/RAF mutation was exclusively detected in non-HBV-related iCCA.
There are quite limited studies discussing the specific prognostic factors respective to HBV seropositive or seronegative in iCCA patients. A small sample size of the study might add an uncertainty to the finding that liver cirrhosis and multiple tumors were only the independent predictive factor for OS in HBV-related iCCA. 8 No study
particularly assessed the prognostic value of the characteristics of the tumor for non-HBV-related iCCA. It has been widely accepted that vascular invasion, lymphatic and extrahepatic metastasis, tumor differentiation, serum levels of AFP, and CA19-9 can independently predict OS for iCCA patients. In this study, among these features, we found serum levels of AFP and extrahepatic metastasis only predicted OS in HBV-related iCCA, and lymphatic metastasis was an independent prognostic factor only in non-HBV-related iCCA.
T A B L E 2 Comparison of clinicopathological and genetic characteristics between HBV-and non-HBV-related iCCA (n = 268)
Variables HBV-related, n = 119 Non-HBV-related, n = 149 P value 
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Particularly, we are the first to discuss the distinctive prognostic roles of TP53 and RAS/RAF mutations in HBV-and non-HBV-related iCCA. Both TP53 mutation and RAS/RAF mutation have been acknowledged having an association with poorer outcomes of iCCA patients, 17 intriguingly, we found TP53 mutation predicted OS independently in HBV-related iCCA, instead of non-HBV-related iCCA, where TP53 mutation only showed an association with poorer outcome in the univariate model. In HBV-related iCCA, no significant difference of demographic and clinicopathologic features was found between mutant and wild-type TP53 groups, but it appeared that T A B L E 3 The factors predicting OS in HBV-and non-HBV-related iCCA (n = 268) iCCA with theTP53 mutation was more likely to have poorer differentiation and vascular invasion (Supporting Information Table   2 ), which requires further confirmation in future. For RAS/RAF mutation, it only predicted OS in non-HBV-related iCCA, which could be explained as RAS/RAF mutation exclusively occurred in non-HBV-related iCCA.
These distinctive prognostic factors between HBV-and non-HBV-related iCCA shed light on utilizing more specific therapy to treat them separately. Strategies to target iCCA with RAS/RAF mutation have focused on downstream of KRAS-related pathways, such as RAF/MEK/ERK and PI3K/AKT, and are quite promising. 18 As RAS/RAF mutation more frequently occurs and exclusively predicts OS in non-HBV-related iCCA, it is reasonable to hypothesize that inhibition of RAS/RAF pathway might produce more benefit for patients with non-HBV-related iCCA but needs confirmation in future. There is no therapy targeting TP53 mutation directly, at present. Understanding genetic alterations and enriched pathways related with theTP53 mutation should be helpful in finding a more efficient way to treat iCCA with TP53 mutation. The HBV-related iCCA appears to obtain more benefit from this kind of therapy, but we still insist using more caution to decide which subtype of iCCA could be more sensitive, as TP53 mutation also predicted OS in non-HBVrelated iCCA in the univariate model.
The effect of routine lymphadenectomy in iCCA is still unclear, 19 ,20 a recent HBV-related iCCA study did not recommend routine lymphadenectomy in patients without suspicion of lymphatic metastasis, as lymphadenectomy did not improve the outcome when compared with the group without lymphadenectomy. 8 In this study, as we found lymphatic metastasis predicted OS for HBV-related iCCA in univariate analysis, therefore, we need to be very careful while saying routine lymphadenectomy is not recommended for patients with HBV-related iCCA. Patients who are highly suspected with lymphatic metastasis should be highly considered for processing lymphadenectomy, as lymph node involvement determines tumor staging and may influence decisions regarding adjuvant therapy. For patients with non-HBV-related iCCA, lymphatic metastasis in preoperative examination should be an indicator for lymphadenectomy, as lymphatic metastasis is a prognostic factor in both univariate and multivariate models.
Our study has several limitations. First, the sample size in this retrospective study was not quite large, an extra online dataset was included to supplement more data, but there is lack of information on histological examination, adjuvant therapy, and antivirus therapy. Second, we did not reveal the convinced mechanisms to explain the different prognostic roles of TP53 and RAS/RAF mutations in HBV-and non-HBV-related iCCA in this study. We truly hope further studies could be launched to better prove and explain this finding. Altogether, HBV-and non-HBVrelated iCCA had distinctive prognostic factors, in particular, TP53 and RAS/RAF mutations predicted OS in HBV-and non-HBV-related iCCA, respectively.
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